London · Delayed Price · Currency is GBP · Price in GBX Smith & Nephew Earnings Call Transcripts
Fiscal Year 2026
-
The event showcased a robust innovation pipeline across wound care, sports medicine, orthopedics, and enabling technologies, with a focus on ASC efficiency and data-driven solutions. Key platforms like CORI, Landmark, AETOS, and TESSA are positioned to drive growth, supported by strong clinical evidence and surgeon advocacy.
-
Q1 delivered 3.1% underlying growth, led by Sports Medicine and resilient Advanced Wound Management, offsetting softness in U.S. knees. Full-year guidance is reaffirmed, with a $500 million share buyback announced and strong cash generation supporting future growth.
Fiscal Year 2025
-
Strong FY2025 results featured 5.3% underlying revenue growth, 160 bps margin expansion, and a 52.5% increase in free cash flow. 2026 guidance targets 6% organic revenue growth and $1.3B trading profit, with innovation and disciplined capital allocation driving performance.
-
RISE strategy aims for 6%-7% organic growth and 9%-10% profit over three years, driven by innovation in sports medicine, wound care, and orthopedics. ASC expansion, new product launches like landmark knee and TESSA, and operational improvements support margin and cash flow goals.
-
The RISE strategy sets ambitious targets for revenue, profit, and patient reach, driven by innovation, operational efficiency, and focused capital allocation. Key growth will come from Sports Medicine, Wound, and ENT, with Orthopaedics returning to market growth and margin expansion. Financial discipline, robust product launches, and a strong culture underpin confidence in achieving these goals.
-
Q3 delivered 5% underlying revenue growth, with strong performance in sports medicine, advanced wound management, and U.S. hips, offset by softness in knees and China. Free cash flow guidance was raised to ~$750 million, and margin expansion is expected to continue despite headwinds from tariffs and reimbursement changes.
-
Q2 saw 6.7% underlying revenue growth and 100 bps margin expansion, with all business units contributing and strong cash flow enabling a $500 million share buyback. Full-year guidance is maintained despite macro uncertainties, with margin and free cash flow expected to rise further in H2.
-
Q1 delivered 3.1% underlying revenue growth, ahead of guidance, with strong innovation and operational improvements. Margin guidance remains unchanged despite tariff headwinds, and sequential growth is expected through 2025 as China and trading day impacts subside.
Fiscal Year 2024
-
Q4 and FY 2024 saw strong growth and margin expansion, driven by innovation, cost savings, and operational improvements, despite significant headwinds from China. Guidance for 2025 includes further revenue growth, margin expansion, and robust free cash flow, with continued focus on efficiency and innovation.
-
Q3 saw 4% revenue growth, driven by strong U.S. and established markets, but China headwinds from VBP and weak demand weighed on results. Full-year growth is now expected at 4.5% with margin guidance lowered to 19%-20% for 2025, as China challenges persist.
-
Q2 saw 5.6% revenue growth and margin expansion, with strong performance in Sports Medicine, Advanced Wound Management, and Orthopedics. Full-year guidance is reaffirmed, cost savings initiatives are expanded, and cash conversion and ROIC are improving.